13 assets in PALB2-Related Cancer Predisposition

Therapeutic assets addressing PALB2-Related Cancer Predisposition, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Niraparib PALB2-Related Cancer Predisposition	Qian Qin	P2	B (59)
Cis-Diamminedichloroplatinum Ii PALB2-Related Cancer Predisposition	University Health Network, Toronto	P2/3	B (57)
Abiraterone PALB2-Related Cancer Predisposition	Qian Qin	P2	CCC (53)
Docetaxel PALB2-Related Cancer Predisposition	Qian Qin	P2	CCC (53)
Dostarlimab PALB2-Related Cancer Predisposition	Dana-Farber Cancer Institute	P2	CCC (53)
Olaparib PALB2-Related Cancer Predisposition	Beth Israel Deaconess Medical Center	P2	CCC (53)
Prednisone PALB2-Related Cancer Predisposition	Qian Qin	P2	CCC (53)
Talazoparib PALB2-Related Cancer Predisposition	M.D. Anderson Cancer Center	P2	CCC (53)
Tamoxifen PALB2-Related Cancer Predisposition	European Institute of Oncology	P2	CCC (53)
Aquocobalamin PALB2-Related Cancer Predisposition	General Oncology, Inc.	P1	CC (43)
Camustine PALB2-Related Cancer Predisposition	General Oncology, Inc.	P1	CC (43)
Irinotecan PALB2-Related Cancer Predisposition	University of California, San Francisco	P1	CC (43)
Melphalan PALB2-Related Cancer Predisposition	General Oncology, Inc.	P1	CC (43)